<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00509431</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000557423</org_study_id>
    <secondary_id>UCLA-0604104</secondary_id>
    <nct_id>NCT00509431</nct_id>
  </id_info>
  <brief_title>Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma</brief_title>
  <official_title>A Phase I/II, Dual-Center, Open-Label Trial of the Safety and Efficacy of Tarceva™ (Erlotinib Hydrochloride) Plus Sirolimus in Patients With Recurrent Malignant Glioma Not on P450-Inducing Anti-Epileptics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Erlotinib and sirolimus may stop the growth of tumor cells by blocking some of the&#xD;
      enzymes needed for cell growth.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects and best dose of erlotinib when&#xD;
      given together with sirolimus and to see how well they work in treating patients with&#xD;
      recurrent malignant glioma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of&#xD;
           escalating doses of erlotinib hydrochloride in combination with sirolimus in adult&#xD;
           patients with malignant glioma, who are not receiving enzyme-inducing anti-epileptic&#xD;
           drugs (EIAED). (Phase I)&#xD;
&#xD;
        -  Evaluate preliminary efficacy (response rate [RR], progression-free survival [PFS], and&#xD;
           overall survival [OS]) of erlotinib hydrochloride and sirolimus combination therapy in&#xD;
           glioblastoma multiforme (GMB)/gliosarcoma (GS) patients who are not undergoing surgery&#xD;
           at the time of recurrence or relapse (dose-expansion arm). (Phase II)&#xD;
&#xD;
        -  Evaluate molecular determinants of response to the combination of erlotinib&#xD;
           hydrochloride and sirolimus, especially the roles of the mutation of EGFR (e.g., vIII&#xD;
           mutant, other somatic mutations of vIII, and mutation/deletion of PTEN).&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To characterize the safety and tolerability of erlotinib hydrochloride and sirolimus&#xD;
           combination therapy in these patient populations.&#xD;
&#xD;
        -  To characterize the single-dose and repeated-dose pharmacokinetic (PK) profiles of&#xD;
           erlotinib hydrochloride (in serum) and sirolimus (in whole blood) combination therapy in&#xD;
           these patient populations.&#xD;
&#xD;
        -  To characterize, in pre- and/or post-treatment tumor samples, when available, expression&#xD;
           levels of total and activated phosphorylated proteins relevant to the EGFR, VEGFR, and&#xD;
           PI3K/mTOR signaling pathways, relevant downstream signaling network components, EGFR and&#xD;
           VEGFR-related ligands, apoptosis (TUNEL), cell cycle control, and proliferation.&#xD;
&#xD;
        -  To assess pre- and/or post-treatment tumor samples, when available, for DNA-based&#xD;
           changes (e.g., EGFR [DNA] amplification, EGFR and EGFRvIII mutations, and&#xD;
           mutations/deletions in the PTEN gene) relevant to the molecular biology in GBM.&#xD;
&#xD;
      OUTLINE: Patients receive oral erlotinib hydrochloride and sirolimus once daily on days 1-28.&#xD;
      Treatment repeats every 28 days in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      Patients undergo tumor tissue and blood sample collection periodically for pharmacological&#xD;
      and biological studies. Samples are analyzed for concentrations of erlotinib hydrochloride&#xD;
      and trough serum levels of sirolimus via HPLC, EGFR, EGFRvIII, PTEN and the phospho-specific&#xD;
      antibodies associated with the MAPK and PI3K pathways via IHC, and EGFRvIII and sequencing of&#xD;
      EGFR, PTEN and other critical genes via PCR, gene expression, and SNP analysis. Germline DNA&#xD;
      will also be used to distinguish polymorphisms from somatic mutations in gene sequenced.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine maximum tolerated dose and dose limiting toxicity of escalating doses of erlotinib in combination with sirolimus</measure>
    <time_frame>day 28 of cycle 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To characterize the single-dose pharmacokinetic (PK) profile of erlotinib (in serum) and sirolimus (in whole blood) combination therapy in these patient populations</measure>
    <time_frame>Day 1 of cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize repeated-dose pharmacokinetic (PK) profile of erlotinib (in serum) and sirolimus (in whole blood) combination therapy in these patient populations</measure>
    <time_frame>Day 28 of cycle 1</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <arm_group>
    <arm_group_label>Erlotinib + Sirolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is an open-label,phase I single-arm dose-escalation and phase II study of continuous, once daily doses of erlotinib administered orally in combination with sirolimus in adult patients with malignant glioma at first, second or third recurrence</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib + Sirolimus</intervention_name>
    <description>In arm I of dose escalation phase,starting dose of erlotinib is 150 mg daily. Starting dose of sirolimus includes a 15 mg loading dose, followed by continuous dosing at 5 mg daily.Dose escalation will proceed according to protocol Phase II of the study was not conducted only Phase I</description>
    <arm_group_label>Erlotinib + Sirolimus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed malignant glioma, including any of the following:&#xD;
&#xD;
          -  Glioblastoma multiforme (GBM)&#xD;
&#xD;
          -  Gliosarcoma (GS)&#xD;
&#xD;
          -  Anaplastic astrocytoma (AA)&#xD;
&#xD;
          -  Anaplastic oligodendroglioma (AO)&#xD;
&#xD;
          -  Anaplastic mixed oligoastrocytomas (AMA)&#xD;
&#xD;
          -  Malignant astrocytoma not otherwise specified (NOS)&#xD;
&#xD;
          -  Prior low-grade glioma allowed provided there is histologic evidence of progression to&#xD;
             a malignant glioma&#xD;
&#xD;
          -  Must meet the following criteria for phase I:&#xD;
&#xD;
          -  All types of malignant gliomas allowed&#xD;
&#xD;
          -  No limitations on the number of relapses&#xD;
&#xD;
          -  Must meet the following criteria for phase II:&#xD;
&#xD;
          -  Only patients with GBM or GS are allowed&#xD;
&#xD;
          -  Must be in first, second, or third relapse&#xD;
&#xD;
          -  patients who had prior therapy (must include external beam radiotherapy) for a&#xD;
             low-grade glioma that is considered standard, non-surgical treatment for a high-grade&#xD;
             glioma, the surgical diagnosis of high-grade glioma will be considered the first&#xD;
             relapse&#xD;
&#xD;
          -  Must have shown unequivocal radiographic evidence for tumor progression by MRI or CT&#xD;
             scan and have either measurable or evaluable disease&#xD;
&#xD;
          -  Measurable disease is defined as bidimensionally measurable lesions with clearly&#xD;
             defined margins by MRI scan&#xD;
&#xD;
          -  Evaluable disease is defined as unidimensionally measurable lesions or masses with&#xD;
             margins not clearly defined&#xD;
&#xD;
          -  Karnofsky performance status ≥ 60%&#xD;
&#xD;
          -  Life expectancy &gt; 8 weeks&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/μL&#xD;
&#xD;
          -  Platelets ≥ 100,000/μL&#xD;
&#xD;
          -  Total bilirubin &lt; 2.0 x upper limit of institutional normal (ULN)&#xD;
&#xD;
          -  AST &lt; 2.0 x ULN&#xD;
&#xD;
          -  Creatinine &lt; 1.5 x ULN&#xD;
&#xD;
          -  Fasting serum triglycerides &lt; 2.5 x ULN&#xD;
&#xD;
          -  Fasting serum cholesterol &lt; 350 mg/dL&#xD;
&#xD;
          -  Women of child-bearing potential and men must agree to use adequate contraception&#xD;
             (i.e., hormonal or barrier method of birth control) prior to study entry and for the&#xD;
             duration of study participation&#xD;
&#xD;
          -  Recovered from all toxicities associated with prior surgery, radiotherapy, or&#xD;
             chemotherapy&#xD;
&#xD;
          -  At least 1 week since prior surgery&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)&#xD;
&#xD;
          -  At least 12 weeks since prior radiation therapy&#xD;
&#xD;
          -  Must not receive any P450-enzyme-inducing anticonvulsants (EIAC) for at least 2 weeks&#xD;
             prior to and during participation in this trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who are pregnant or lactating&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to erlotinib hydrochloride or sirolimus&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, any of the following:&#xD;
&#xD;
          -  Ongoing or active infection requiring IV antibiotics&#xD;
&#xD;
          -  Symptomatic congestive heart failure&#xD;
&#xD;
          -  Unstable angina pectoris&#xD;
&#xD;
          -  Cardiac arrhythmia&#xD;
&#xD;
          -  Hyperlipidemia (e.g., grade 3 or greater hypercholesterolemia or hypertriglyceridemia)&#xD;
             not controlled with medication&#xD;
&#xD;
          -  Psychiatric illness or social situations that would limit compliance with study&#xD;
             requirements&#xD;
&#xD;
          -  Disorders associated with significant immunocompromise (e.g., HIV or systemic lupus&#xD;
             erythematosus [SLE])&#xD;
&#xD;
          -  Patients with another primary malignancy that has required treatment other than&#xD;
             surgery within the past year (except for nonmelanoma skin cancer or carcinoma in situ)&#xD;
&#xD;
          -  Patients with the inability to comply with the protocol requirements in the opinion of&#xD;
             the investigator including those who can not take oral medications&#xD;
&#xD;
          -  Patients who are unable to undergo routine imaging evaluations with magnetic resonance&#xD;
             imaging scans&#xD;
&#xD;
          -  Prior EGFR-directed or mTOR-directed therapies including sirolimus or sirolimus&#xD;
             analogs&#xD;
&#xD;
          -  Patients taking concurrent immunosuppressive agents other than prescribed&#xD;
             corticosteroids&#xD;
&#xD;
          -  Concurrent antineoplastic or antitumor agents that are not part of the study therapy&#xD;
             including chemotherapy, radiation therapy, immunotherapy, and hormonal anticancer&#xD;
             therapy&#xD;
&#xD;
          -  Blood products during cycle 1 unless a patient experiences hematologic DLT or if it is&#xD;
             medically imperative to administer a transfusion&#xD;
&#xD;
          -  Concurrent grapefruit or grapefruit juice&#xD;
&#xD;
          -  Other concurrent investigational agents&#xD;
&#xD;
          -  Receiving concurrent enzyme-inducing antiepileptic drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy F. Cloughesy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>July 30, 2007</study_first_submitted>
  <study_first_submitted_qc>July 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2007</study_first_posted>
  <last_update_submitted>July 29, 2020</last_update_submitted>
  <last_update_submitted_qc>July 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult anaplastic oligodendroglioma</keyword>
  <keyword>adult mixed glioma</keyword>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult pilocytic astrocytoma</keyword>
  <keyword>adult diffuse astrocytoma</keyword>
  <keyword>adult subependymal giant cell astrocytoma</keyword>
  <keyword>adult oligodendroglioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

